Answers are grounded in this paper and cite their sources.
Analysis shows combined anticoagulant therapy increases cardiovascular death in older patients with atrial fibrillation, suggesting warfarin's limitations.
In older patients with atrial fibrillation, OAC+APD therapy was associated with higher incidence of cardiovascular death than OAC monotherapy, without significant differences in other clinical outcomes. For patients requiring combination therapy, DOACs may be preferable to warfarin.
No takes yet. Share an insight, caveat, or question.
Kamogawa et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: